Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP4 | P49662 | 1/20 | 0.38 |
| ▸ | CASP5 | P51878 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890908 | 0.91 | TRPV1 (0.50) | TRPV1MTORHSD11B1 | |
| SCHEMBL13761534 | 0.91 | TRPV1 (0.47) | TRPV1MTORPIM1HSD11B1 | |
| SCHEMBL3881501 | 0.91 | TRPV1 (0.47) | TRPV1MTORPIM1HSD11B1 | |
| SCHEMBL3880689 | 0.89 | TRPV1 (0.51) | TRPV1MTORPIM1HSD11B1GSK3B | |
| SCHEMBL13761532 | 0.89 | TRPV1 (0.51) | TRPV1MTORPIM1HSD11B1GSK3B | |
| SCHEMBL3880528 | 0.88 | TRPV1 (0.44) | TRPV1HSD11B1 | |
| SCHEMBL3879871 | 0.88 | TRPV1 (0.48) | TRPV1HSD11B1 | |
| SCHEMBL3889935 | 0.88 | TRPV1 (0.52) | TRPV1HSD11B1 | |
| SCHEMBL13761516 | 0.88 | TRPV1 (0.48) | TRPV1HSD11B1 | |
| SCHEMBL14613871 | 0.87 | TRPV1 (0.49) | TRPV1PIM1HSD11B1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | TRPV1 244/4885MTOR 2949/4885PIM1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.